Zdrowie i gospodarka · 31/01/2013
FDA Clears Adapalene Solution for Approval via ANDA Process
The FDA has determined that adapalene solution, 0.1%, was not withdrawn from sale due to safety or effectiveness concerns. This decision enables the FDA to approve ANDA applications for adapalene solution, 0.1%, pending compliance with all applicable regulations.
Source: Federal Register — Food and Drug AdministrationOpen original release →